Although current evidence suggests that IDH1 mutation catalyzes the reduction of α-ketoglutarate (α-KG) into D-2-hydroxyglutarate (D-2HG) [9, 10], which has been linked to distinctive cancer metabolism and signaling cascade patterns, contributing to malignant transformation, progression, and therapeutic resistance [11–13]. This evidence concerns the gene IDH1 and cancer.